Zidovudine for symptomless HIV infection.
D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D015704:CD4 Antigens / Q000032:analysis; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004341:Drug Evaluation; D004361:Drug Tolerance; D006679:HIV Seropositivity / Q000097:blood / Q000188:drug therapy*; D006291:Health Policy / Q000639:trends*; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration; D015215:Zidovudine / Q000009:adverse effects / Q000627:therapeutic use*
D015704:CD4 Antigens; D015215:Zidovudine